These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 25958125)

  • 1. Is HbA1c a valid surrogate for macrovascular and microvascular complications in type 2 diabetes?
    Bejan-Angoulvant T; Cornu C; Archambault P; Tudrej B; Audier P; Brabant Y; Gueyffier F; Boussageon R
    Diabetes Metab; 2015 Jun; 41(3):195-201. PubMed ID: 25958125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood glucose reduction by diabetic drugs with minimal hypoglycaemia risk for cardiovascular outcomes: Evidence from meta-regression analysis of randomized controlled trials.
    Huang CJ; Wang WT; Sung SH; Chen CH; Lip GYH; Cheng HM; Chiang CE
    Diabetes Obes Metab; 2018 Sep; 20(9):2131-2139. PubMed ID: 29722116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.
    Heller SR; Bergenstal RM; White WB; Kupfer S; Bakris GL; Cushman WC; Mehta CR; Nissen SE; Wilson CA; Zannad F; Liu Y; Gourlie NM; Cannon CP;
    Diabetes Obes Metab; 2017 May; 19(5):664-671. PubMed ID: 28058763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
    Hemmingsen B; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of glucose-lowering on outcome incidence in diabetes mellitus and the modulating role of blood pressure and other clinical variables: overview, meta-analysis of randomized trials.
    Thomopoulos C; Bazoukis G; Ilias I; Tsioufis C; Makris T
    J Hypertens; 2019 Oct; 37(10):1939-1949. PubMed ID: 31157748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
    Madsen KS; Chi Y; Metzendorf MI; Richter B; Hemmingsen B
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD008558. PubMed ID: 31794067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus.
    Fullerton B; Jeitler K; Seitz M; Horvath K; Berghold A; Siebenhofer A
    Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD009122. PubMed ID: 24526393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The haemoglobin glycation index as predictor of diabetes-related complications in the AleCardio trial.
    van Steen SC; Schrieks IC; Hoekstra JB; Lincoff AM; Tardif JC; Mellbin LG; Rydén L; Grobbee DE; DeVries JH;
    Eur J Prev Cardiol; 2017 May; 24(8):858-866. PubMed ID: 28186441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Legacy effect of intensive glucose control on major adverse cardiovascular outcome: Systematic review and meta-analyses of trials according to different scenarios.
    Prattichizzo F; de Candia P; De Nigris V; Nicolucci A; Ceriello A
    Metabolism; 2020 Sep; 110():154308. PubMed ID: 32628943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.
    Hemmingsen B; Lund SS; Gluud C; Vaag A; Almdal TP; Hemmingsen C; Wetterslev J
    Cochrane Database Syst Rev; 2013 Nov; (11):CD008143. PubMed ID: 24214280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials.
    Boussageon R; Bejan-Angoulvant T; Saadatian-Elahi M; Lafont S; Bergeonneau C; Kassaï B; Erpeldinger S; Wright JM; Gueyffier F; Cornu C
    BMJ; 2011 Jul; 343():d4169. PubMed ID: 21791495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Test in Context: Hemoglobin A
    Gore MO; McGuire DK
    J Am Coll Cardiol; 2016 Dec; 68(22):2479-2486. PubMed ID: 27908354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of glycaemic control and hypoglycaemic episodes to 4-year cardiovascular outcomes in people with type 2 diabetes starting insulin.
    Freemantle N; Danchin N; Calvi-Gries F; Vincent M; Home PD
    Diabetes Obes Metab; 2016 Feb; 18(2):152-8. PubMed ID: 26511332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemoglobin A1c variability as an independent correlate of cardiovascular disease in patients with type 2 diabetes: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study.
    Penno G; Solini A; Zoppini G; Orsi E; Fondelli C; Zerbini G; Morano S; Cavalot F; Lamacchia O; Trevisan R; Vedovato M; Pugliese G;
    Cardiovasc Diabetol; 2013 Jul; 12():98. PubMed ID: 23829205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Visit-to-Visit HbA
    Li S; Nemeth I; Donnelly L; Hapca S; Zhou K; Pearson ER
    Diabetes Care; 2020 Feb; 43(2):426-432. PubMed ID: 31727686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling incremental benefits on complications rates when targeting lower HbA
    Mostafa SA; Coleman RL; Agbaje OF; Gray AM; Holman RR; Bethel MA
    Diabet Med; 2018 Jan; 35(1):72-77. PubMed ID: 29057545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.